Bio Medica Laboratories (NSE:BMLL) LT-Debt-to-Total-Asset: 0.17 (As of Mar. 2025)


NSE:BMLL Bio Medica Laboratories Ltd NSE:BMLL
14 GF Score
Price ₹144.10
! 2 Warning Signs
View Full Analysis

What is Bio Medica Laboratories LT-Debt-to-Total-Asset?

Bio Medica Laboratories NSE:BMLL +0.49% 14 LT-Debt-to-Total-Asset is 0.17 as of Mar. 2025. GuruFocus rates NSE:BMLL with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bio Medica Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2025 was 0.17.

Bio Medica Laboratories's long-term debt to total assets ratio declined from Mar. 2023 (0.27) to Mar. 2025 (0.17). It may suggest that Bio Medica Laboratories is progressively becoming less dependent on debt to grow their business.

Bio Medica Laboratories  (NSE:BMLL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bio Medica Laboratories LT-Debt-to-Total-Asset Related Terms

Bio Medica Laboratories LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Bio Medica Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio Medica Laboratories LT-Debt-to-Total-Asset Chart

Bio Medica Laboratories Annual Data
Trend Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset
0.27 0.40 0.17

Bio Medica Laboratories Semi-Annual Data
Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset 0.27 0.40 0.17
NSE:BMLL
14GF Score
Bio Medica Laboratories Ltd NSE:BMLL
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio Medica Laboratories LT-Debt-to-Total-Asset Calculation

Bio Medica Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )/Total Assets (A: Mar. 2025 )
=67.648/391.179
=0.17

Bio Medica Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (Q: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )/Total Assets (Q: Mar. 2025 )
=67.648/391.179
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.17 mean?
Bio Medica Laboratories (NSE:BMLL) has a LT-Debt-to-Total-Asset of 0.17 as of Mar. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bio Medica Laboratories and its competitors.
Is Bio Medica Laboratories' LT-Debt-to-Total-Asset too high?
Bio Medica Laboratories' current LT-Debt-to-Total-Asset is 0.17. Overall, Bio Medica Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' LT-Debt-to-Total-Asset compare to ISRG and BDX?
Bio Medica Laboratories' LT-Debt-to-Total-Asset of 0.17 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bio Medica Laboratories and its competitors. Bio Medica Laboratories's current LT-Debt-to-Total-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current LT-Debt-to-Total-Asset of 0.17. The current LT-Debt-to-Total-Asset is 0.17. Bio Medica Laboratories' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current LT-Debt-to-Total-Asset is 0.17 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio Medica Laboratories Business Description

Address Sanwer Road, Plot No. 11B-11C, Sector-E, Industrial Area, Industrial Estate - Indore, Indore, MP, IND, 452015
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
14GF Score

Get the complete analysis for NSE:BMLL

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹144.10
Price